Skip to Content

'
Emer O. Hanrahan, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 432
Houston, TX 77030
Room Number: FCT9.5085
Phone: 713-792-6363
Fax: 713-792-1220

Education & Training

Degree-Granting Education

1999 University of Dublin, Trinity College, Dublin, Ireland, BA, Biology
1999 University of Dublin, Trinity College, Dublin, Ireland, MD, Medicine

Postgraduate Training

9/2006-11/2008 Clinical Fellowship, Medical Oncology (years 2 and 3), The University of Texas M. D. Anderson Cancer Center, Houston, TX
7/2005-9/2006 Clinical Fellowship, Medical Oncology (year 1), National Cancer Institute, Bethesda, MD
7/2004-6/2005 Clinical Fellowship, Interdisciplinary Breast Cancer, The University of Texas M. D. Anderson Cancer Center, Houston, TX
7/2002-6/2004 Specialist Registrar Training, Medical Oncology, Royal College of Physicians of Ireland, Dublin, Ireland
7/1999-6/2002 Clinical Residency, Internal Medicine, Royal College of Physicians of Ireland, Dublin, Ireland

Selected Publications

Peer-Reviewed Original Research Articles
1. Hanrahan EO, Kies MS, Glisson BS, Khuri FR, Feng L, Tran HT, Ginsberg LE, Truong MT, Hong WK, Kim ES. A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck. Am J Clin Oncol 32(3):274-9, 2009. e-Pub 5/2009. PMID: 19433965.
2. Hanrahan EO, Ryan AJ, Mann H, Kenedy S, Langmuir P, Natale RB, Herbst RS, Johnson BE, heymach JV. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15(10):3600-9, 2009. PMID: 19447868.
3. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 25(31):4952-60, 11/2007. PMID: 17971593.
4. Hanrahan EO, Heymach JV. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res 13(13):4617s-22s, 2007. PMID: 17671152.
5. Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer 106(11):2327-36, 6/2006. PMID: 16639731.
6. Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol 24(13):2113-22, 5/2006. PMID: 16648513.
7. Blancas I, Garcia-Puche JL, Bermejo B, Hanrahan EO, Monteagudo C, Martinez-Agullo A, Rouzier R, Henessy BT, Valero V, Luch A. Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor. Ann Oncol(17):1644-9, 2006.
8. Hanrahan EO, Hennessy BT, Valero V. Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert Opin Pharmacother 6(9):1477-91, 2005. PMID: 16086636.

Last updated: 9/3/2009